Publication | Closed Access

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

Columbia University ExperiencePancreatic CancerMedicinePharmacologyPathologyMolecular OncologyPancreas CenterOncologyCancer ResearchEndocrine-related CancerWell-differentiated Neuroendocrine Cancers